In real-world settings, a study conducted using Danish registers employed a nested case–control design to assess the effects of GLP-1 agonists by comparing prevalent users and non-users in patients with T2DM and dementia and their matched controls.22 The gene discussed is GCG; the disease is type 2 diabetes mellitus.